Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Cinnamic Acid Derivatives for Treating Metabolic Syndrome
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Cinnamic acid derivatives are good candidates to satisfy this unmet medical need...
Contact
Participants
You
Email me a copy of this message

Executive Summary


BioNutrigen, Inc (“BioNutrigen”) was organized in 1999 by scientists from the Korean Research Institute of Bioscience and Biotechnology. BioNutrigen has been focused on developing non-toxic natural products and materials from vegetables and fruits for prevention or treatment of adult disease such as obesity, diabetes and CV diseases.


Cinnamic acid derivatives were extracted from natural sources (e.g., apple, tea, potato, coffee, grape, plum and etc) and used to prevent and treat blood lipid level-related diseases such as hyperlipidemia, arteriosclerosis, angina pectoris, stroke and fatty liver. Use of novel cinnamic acid derivatives to treat or prevent Metabolic Syndrome are protected by worldwide patents held by BioNutrigen.


It estimates that there are nearly 86 million Metabolic Syndrome patients in the six major markets. There are no medicines approved for treatment for Metabolic Syndrome and the lack of a safe and effective medicine for this indication creates an unmet medical need in major global markets around the world.





Fig.1 Cinnamic acid derivatives




Cinnamic acid derivatives are good candidates to satisfy this unmet medical need. Promising preclinical data generated over the past 8 years by BioNutrigen scientists makes cinnamic acid derivatives a “first-in-class” series of compounds targeted at the Metabolic Syndrome indication. BioNutrigen is seeking co-development partners or licensing partners to fund the clinical development an innovative and promising medicine, cinnamic acid derivatives.


Key Technology Highlights


Lowering blood cholesterol level


Cinnamic acid derivatives can improve lipid metabolism and liver function. These drugs also inhibit plaque formation in the endothelium of the main artery and diminish formation of fatty liver, as shown below compared to other commercial agents.






Group






TC


(mg/dl)






TG


(mg/dl)






HDL-C


(mg/dl)






HDL/TC


(%)






GOT


(IU/l)






GPT


(IU/l)






Fatty streak (%)






A






Control






1995+ 472






170 +30






50 + 11






2.5 + 0.4






161+ 71






96 + 46






80 + 8






3.2 + 0.3






Lovastatin






1446 + 263






153 + 95






58 + 23






4.9 + 2.6






43 + 12






81 + 44






15 + 3






3.4 + 0.5






4-hydroxycinnamic acid






1517 + 417






167 + 43






57 + 28






3.7 + 1.3






59 + 45






74 + 49






24 + 11






2.7 + 0.3






3,4-dihydroxycinnamic acid






1559 + 347






139 + 46






53 + 13






3.4 + 0.4






99 + 49






40 + 27






13 + 5






2.6 + 0.3






3,4-dihydroxyhydrocinnamic acid






1256 + 150






108 + 22






80 + 23






6.3 + 1.6






55 + 20






90 + 83






16 + 1






2.6 + 0.3






Inhibition of HMG-CoA reductase activity


HMG-CoA reductase activities observed with the 4-hydroxycinnamic acid, 3,4-dihydroxycinnamic acid and 3,4-dihydroxyhydrocinnamic acid groups are lower than that of the Control group by 31 to 70%.






Group






Inhibition of


HMG-CoA reductase activity (%)






Control






0






4-hydroxycinnamic acid






31






3,4-dihydroxycinnamic acid






44





FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
GOVERNMENT INSTITUTE